Selank and Semax: Nootropic Peptides in Neuroscience Research

For research purposes only. Not for human consumption or therapeutic use. Neither Selank nor Semax is approved by the FDA or EMA.

Selank and Semax are two synthetic peptides developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. Both are built from short native regulatory sequences. And both are often labeled “nootropic peptides” in the literature, though that label describes a research context, not a clinical outcome.

This guide compares the two side by side.

Selank vs Semax at a glance

Selank and Semax are frequently discussed in the same breath. They are not the same molecule. They do not share a parent peptide. And their proposed mechanisms act on different receptor systems. The table below summarizes the key differences.

Property	Selank	Semax
Sequence	Thr-Lys-Pro-Arg-Pro-Gly-Pro	Met-Glu-His-Phe-Pro-Gly-Pro
Parent peptide	Tuftsin (immunomodulatory tetrapeptide)	ACTH(4-10) fragment (neurotrophic)
Molecular weight	~751 Da	~813 Da
Primary proposed mechanism	GABAergic modulation, enkephalin metabolism	BDNF/NGF expression, MAPK/ERK signaling
Key research areas	Anxiolytic-like behavior, immune signaling	Cerebrovascular models, cognitive endpoints
Methionine residue	No	Yes (Met1, oxidation sensitive)
Origin lab	Institute of Molecular Genetics, Moscow	Institute of Molecular Genetics, Moscow

Origins: two peptides from the same Russian tradition

Both peptides emerged from the same research program in Moscow. Selank was designed from tuftsin, a naturally occurring tetrapeptide released from IgG heavy chain cleavage. Tuftsin is known for its immunomodulatory effects. Adding a C-terminal Pro-Gly-Pro extension produced Selank, a heptapeptide with improved metabolic stability.

Semax took a different parent. Early studies of adrenocorticotropic hormone (ACTH) found that the ACTH(4-10) fragment retained neurotrophic activity independent of adrenal steroid release. Researchers trimmed and modified that fragment, then applied the same Pro-Gly-Pro stabilization trick. The result was Semax.

This shared lineage matters for researchers. Both peptides share the same C-terminal extension. Both were developed to resist aminopeptidase degradation. And both are designed around the idea that short peptides can carry the regulatory signal of much larger parent molecules.

Selank mechanism of action

Selank has been studied primarily in the context of anxiety-like behavioral models and immune signaling. Its proposed mechanisms involve several distinct pathways.

GABAergic modulation

Published research suggests Selank may influence the GABAergic system. Studies in animal models have reported changes in GABA-A receptor subunit expression after Selank administration. Unlike benzodiazepines, which bind GABA-A receptors directly, Selank appears to act through indirect modulation. The exact receptor-level interaction is still under investigation.

BDNF expression

Brain-derived neurotrophic factor (BDNF) is a key neurotrophin involved in synaptic plasticity. Several preclinical studies have reported associations between Selank administration and altered BDNF mRNA expression in specific brain regions. These are mRNA-level observations. They should not be read as direct evidence of protein-level functional change.

Enkephalin metabolism

Selank has been reported to inhibit enzymes involved in enkephalin degradation. This would potentially prolong endogenous opioid peptide signaling without direct opioid receptor binding. This mechanism is distinct from classical opioid pharmacology and remains an active area of investigation.

Semax mechanism of action

Semax research focuses on neurotrophic factor regulation and cerebrovascular endpoints. Its proposed mechanisms are different from Selank’s.

Neurotrophic factor upregulation

Published research associates Semax administration with increased expression of BDNF, nerve growth factor (NGF), and glial cell line-derived neurotrophic factor (GDNF) in preclinical models. These effects appear to operate independently of melanocortin receptor binding, despite Semax’s parent sequence deriving from ACTH. The signaling downstream is reported to involve MAPK/ERK cascades.

Cerebrovascular preclinical models

Semax has been studied in animal models of cerebral ischemia. Published reports describe associations with reduced infarct volume and altered neurological scores in these models. These findings are limited to rodent models and should not be extrapolated to human clinical outcomes.

Transcriptomic effects

Gene expression studies in the rat brain have reported that Semax administration affects hundreds of genes. The pathways involved span immune response, neurotransmission, and vascular function. This breadth is consistent with a peptide acting upstream of multiple signaling cascades rather than at a single receptor.

The Pro-Gly-Pro extension

Both peptides share the C-terminal Pro-Gly-Pro tripeptide. This is not an accident of design. The extension reduces susceptibility to aminopeptidase cleavage, extending the functional window in biological systems.

Pro-Gly-Pro (PGP) is also biologically active on its own. It has been independently studied in neutrophil chemotaxis and inflammatory signaling. Whether the Pro-Gly-Pro tail contributes to the Selank and Semax profile, or acts purely as a metabolic shield, remains an open question. Researchers designing dose-response studies should be aware of this ambiguity.

Russian neuroscience tradition and Western replication

Most primary literature on Selank and Semax comes from Russian institutions. The Institute of Molecular Genetics, the Institute of Experimental Medicine, and associated groups have published the majority of peer-reviewed work on both peptides. Journals like Bulletin of Experimental Biology and Medicine and Neuroscience and Behavioral Physiology carry many of these findings.

Western replication has been limited. This is partly a funding pattern. Neither peptide has a Western commercial sponsor pursuing clinical development. It is also partly a regulatory pattern. Both compounds are approved as pharmaceuticals in Russia but lack EMA or FDA authorization. The asymmetry means researchers working with Selank or Semax should cross-reference original Russian sources rather than relying solely on English-language reviews. PubMed indexes many of these papers, but not all.

This same dynamic appears with other peptides from the Russian regulatory peptide tradition, including those covered in our neuroprotective peptides in longevity research guide.

Handling and storage

Both peptides are supplied as lyophilized powders. Reconstitution uses bacteriostatic water. Unreconstituted vials are stored at -20 C. Once reconstituted, solutions are kept at 2-8 C and typically used within 21-28 days.

Semax has one additional handling concern. Its N-terminal methionine (Met1) is susceptible to oxidation. Light, heat, and trace metal ions accelerate this. Amber vials and foil wrapping are standard precautions. Selank lacks methionine and is somewhat more stable under comparable conditions.

For quality control, researchers should verify purity by HPLC (>=98 percent) and confirm the correct molecular weight by mass spectrometry. Residual trifluoroacetic acid from synthesis can affect pH-sensitive experiments and should be documented on the certificate of analysis. For broader terminology, see our peptide research terminology glossary.

Frequently asked questions

Is Selank the same as Semax?

No. They are two different synthetic peptides with different sequences, different parent molecules, and different proposed mechanisms. Selank derives from tuftsin and is studied for GABAergic and immune effects. Semax derives from an ACTH fragment and is studied for neurotrophic factor expression. They share only the C-terminal Pro-Gly-Pro stabilization extension and the same originating research tradition.

What is the molecular weight of Selank?

Selank has a molecular weight of approximately 751 Da. Its sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro. Mass spectrometry is the standard verification method, and research-grade material should be cross-checked against the expected monoisotopic mass.

Are Selank and Semax FDA approved?

No. Neither Selank nor Semax has FDA or EMA approval. Both are approved as pharmaceuticals in Russia, where they were developed at the Institute of Molecular Genetics. In the EU and US they are available only for research purposes as synthetic peptides. They are not approved drugs for any human indication in these jurisdictions.

Research-grade material from CertaPeptides

CertaPeptides supplies both peptides as research vials. Their product pages show the class-level specification on record, and we send selected lots to Janoshik for independent testing. Available formats include Selank 5 mg, Selank 10 mg, Semax 5 mg, Semax 10 mg, and a combined Semax + Selank Blend 20 mg.

Strictly for research purposes only. Not for human consumption or therapeutic use. Neither compound is approved by the FDA or EMA for any clinical indication. The term “nootropic” in this article describes a research context, not a clinical outcome or medical claim.

References

1. Uchakina ON, et al. (2008). Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 108(5), 71-75. PMID: 18577961.
2. Kozlovskii II, Danchev ND. (2003). The optimizing action of the synthetic peptide Selank on a conditioned active avoidance reflex in rats. Neuroscience and Behavioral Physiology, 33(7), 639-643. PMID: 14552529.